A randomized phase 3 study of ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of metastatic non–small cell lung cancer: HARMONi-3.Jianjun Zhang, Shun Lu, Hui Wang et al.|Journal of Clinical Oncology|2025Cited by 2